Your session is about to expire
← Back to Search
Transcatheter Valve Replacement
Transcatheter Valve Intervention for Tricuspid Regurgitation
N/A
Recruiting
Research Sponsored by Jenscare Innovation Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Age ≥18 years at time of consent
* Severe or greater TR assessed on transthoracic echocardiography by Echocardiography Core Lab using a 5-grade classification (Mild, Moderate, Severe, Massive, Torrential).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 30 days and at 1 year post-procedure
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test a new device, the LuX-Valve Plus System, in patients with severe tricuspid regurgitation who are not suitable for surgery. The study will evaluate how
Who is the study for?
This trial is for adults over 18 with severe heart murmur or tricuspid valve regurgitation, who are symptomatic but considered unsuitable for surgery by a Heart Team. They must understand the study and consent to participate, be on stable diuretic medication, and have their condition confirmed by specialized labs.
What is being tested?
The LuX-Valve Plus System is being tested in this trial. It's a non-surgical procedure designed to replace the tricuspid valve through a vein (transcatheter intervention) in patients at high risk from traditional surgery.
What are the potential side effects?
While specific side effects aren't listed here, transcatheter interventions can generally include bleeding, infection at the catheter insertion site, heart rhythm problems (arrhythmias), or damage to blood vessels.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My heart valve leak is severe or worse, confirmed by an echo.
Select...
My heart condition limits my physical activity.
Select...
I understand the study details and can give my written consent.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 30 days and at 1 year post-procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 30 days and at 1 year post-procedure
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
- Incidence of major adverse events at 30 days post procedure
- Post-procedural TR Remission Rate
Secondary study objectives
Acute Secondary Endpoints - Clinical success Rate
Acute Secondary Endpoints - Intraprocedural success Rate
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: : LuX-Valve Plus transvenous tricuspid valve and delivery system(LuX-Valve Plus System)Experimental Treatment1 Intervention
The LuX-Valve Plus System is intended for the treatment of patients with severe TR who are determined by a Heart Team to be at high risk of traditional open-heart surgery.
Find a Location
Who is running the clinical trial?
Cardiovascular Research Foundation, New YorkOTHER
27 Previous Clinical Trials
27,205 Total Patients Enrolled
Jenscare Innovation Inc.Lead Sponsor